Evidence map›Paper›PMID 37387486›Full record

ReviewAnnals of laboratory medicine2023

Clot Waveform Analysis for Hemostatic Abnormalities.

Hideo Wada, Katsuya Shiraki, Takeshi Matsumoto, Hideto Shimpo, Motomu Shimaoka

Open access · diamondAbstract readReview
In one paragraph

Review in Annals of laboratory medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Usefulness of Clot Waveform Analysis-Activated Thromboplastin Time (APTT) for Diagnosing Thrombotic Diseases.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
  9. Clinical Application of Clot Waveform Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
  10. Detection of a Prethrombotic State in Patients with Hepatocellular Carcinoma, Using a Clot Waveform Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Hideo WadaDepartment of Laboratory and General Medicine, Mie Prefectural General Medical Center, Yokkaichi, Japan.ORCID 0000-0001-9021-8633
Katsuya ShirakiDepartment of Laboratory and General Medicine, Mie Prefectural General Medical Center, Yokkaichi, Japan.ORCID 0000-0002-5164-1866
Takeshi MatsumotoDepartment of Transfusion Medicine and Cell Therapy, Mie University Hospital, Tsu, Japan.ORCID 0000-0003-3389-0081
Hideto ShimpoMie Prefectural General Medical Center, Yokkaichi, Japan.ORCID 0000-0002-0897-6003
Motomu ShimaokaDepartment of Molecular Pathobiology and Cell Adhesion Biology, Mie University Graduate School of Medicine, Tsu, Japan.ORCID 0000-0001-5764-2598
Mie Chuo Medical Center · JPMie University · JPMie University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clot waveform analysis (CWA) observes changes in transparency in a plasma sample based on clotting tests such as activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT). Evidence indicates that not only an abnormal waveform but also peak times and heights in derivative curves of CWA are useful for the evaluation of hemostatic abnormalities. Modified CWA, including the PT with APTT reagent, dilute PT (small amount of tissue factor [TF]-induced clotting factor IX [FIX] activation; sTF/FIXa), and dilute TT, has been proposed to evaluate physiological or pathological hemostasis. We review routine and modified CWA and their clinical applications. In CWA-sTF/FIXa, elevated peak heights indicate hypercoagulability in patients with cancer or thrombosis, whereas prolonged peak times indicate hypocoagulability in several conditions, including clotting factor deficiency and thrombocytopenia. CWA-dilute TT reflects the thrombin burst, whereas clot-fibrinolysis waveform analysis reflects both hemostasis and fibrinolysis. The relevance and usefulness of CWA-APTT and modified CWA should be further investigated in various diseases.

Indexed as

HemostaticsThrombosisHemostasisHumansProthrombin TimeThrombinHemostaticsThrombinClot waveform analysisFibrinolysisHemostasisHemostaticsIndicators and reagentsProthrombin timeThrombinThrombocytopeniaThrombophiliaThrombosis

Identifiers

PMID37387486
PMCPMC10345169
OpenAlexW4382630812

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.